Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
News|Articles|October 2, 2026
9 Cardiology Headlines You Missed in Q3 2026
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
The third quarter of 2026 was a busy one for cardiology, with several monumental approvals from the
Related to this article
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement